SARS-CoV-2 vaccination in IBD: more pros than cons - Université de Lorraine Access content directly
Journal Articles Nature reviews. Gastroenterology & hepatology Year : 2021

SARS-CoV-2 vaccination in IBD: more pros than cons

Abstract

Data on the efficacy and safety of SARS-CoV-2 vaccines are now available, but evidence for these vaccines in those who are immunocompromised (including patients with inflammatory bowel diseases) are lacking. As vaccination begins, questions on advantages and disadvantages can be partially addressed using the experience from other vaccines or immune-mediated inflammatory disorders.

Dates and versions

hal-03421547 , version 1 (09-11-2021)

Identifiers

Cite

Ferdinando D’amico, Christian Rabaud, Laurent Peyrin-Biroulet, Silvio Danese. SARS-CoV-2 vaccination in IBD: more pros than cons. Nature reviews. Gastroenterology & hepatology, 2021, 18 (4), pp.211-213. ⟨10.1038/s41575-021-00420-w⟩. ⟨hal-03421547⟩
19 View
0 Download

Altmetric

Share

Gmail Facebook X LinkedIn More